The global toxoplasmosis treatment industry generated $683.1M in 2021, and is anticipated to generate $1.09B by 2031, witnessing a CAGR of 4.8% from 2022 to 2031, according to a report from Allied Market Research.
Increase in awareness about foodborne illness, surge in government support for healthcare infrastructure, rise in parasitic infection, and upsurge in use of daraprim drug for the treatment of toxoplasmosis infections drive the growth of the global toxoplasmosis treatment market. However, side effects of toxoplasmosis drugs such as toxic epidermal necrolysis, erythema multiforme, and hyperphenylalaninemina hinder the market growth. Moreover, rise in product launches